# US 2025/0082576 A1 · Cationic lipid compound, composition containing same and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082576 A1
- Document ID: US20250082576A1
- Status: Published application
- Kind: A1
- Application number: 18/956,799
- Filed: 2024-11-22
- Published: 2025-03-13
- Earliest claimed: 2022-01-13
- Assignees: Hangzhou Tianlong Pharmaceutical Co., Ltd.
- Applicants: Hangzhou Tianlong Pharmaceutical Co., Ltd.
- Inventors: Gengshen Song; Huanyu Wang; Honglei Zhang; Xichao Chen; Xiaowen Yu; Dawei Huang
- Web page: https://patentgrep.com/patent/US20250082576A1

## CPC

- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07C 229/16: to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided in the present disclosure are a compound of formula (I), or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof. Further provided are a composition containing the aforementioned compound, and the use thereof in the delivery of a therapeutic agent or prophylactic agent.

## Claims

### Claim 1

A compound of formula (I)
or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein
G1 is C3˜5alkylene;
G2 is C2˜5alkylene;
G3 is C2alkylene;
L1 is C8˜12 linear alkyl;
L2 is C18 branched alkyl.

### Claim 2 (depends on 1)

The compound of formula (I) according to claim 1, or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound of formula (I) has one of the following structures:

### Claim 3 (depends on 1)

A composition comprising a carrier, wherein the carrier comprises a cationic lipid, and the cationic lipid contains the compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to claim 1.

### Claim 4 (depends on 3)

The composition according to claim 3, wherein the molar ratio of the cationic lipid to the carrier is from 30% to 70%.

### Claim 5 (depends on 3)

The composition according to claim 3, wherein the carrier further comprises a neutral lipid;
preferably, the molar ratio of the cationic lipid to the neutral lipid is from 1:1 to 10:1;
preferably, the neutral lipid comprises one or more of phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, ceramide, sterol and a derivative thereof; or
preferably, the neutral lipid is selected from one or more of 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), dipalmitoyl phosphatidylglycerol (DPPG), palmitoyl oleoyl phosphatidylethanolamine (POPE), distearoyl-phosphatidyl-ethanolamine (DSPE), dipalmitoyl phosphatidylethanolamine (DPPE), dimyristoyl phosphoethanolamine (DMPE), 1-stearyl-2-oleoyl-stearoylethanolamine (SOPE), 1-stearoyl-2-oleoyl-phosphatidylcholine (SOPC), sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyl oleoyl phosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine (LPE), and mixtures thereof.

### Claim 6 (depends on 3)

The composition according to claim 3, wherein the carrier further comprises a structured lipid;
preferably, the molar ratio of the cationic lipid to the structured lipid is from 1:1 to 5:1; or
preferably, the structured lipid is selected from one or more of cholesterol, nonsterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatine, tomatine, ursolic acid, alpha-tocopherol, and corticosteroid.

### Claim 7 (depends on 3)

The composition according to claim 3, wherein the carrier further comprises a polymer-conjugated lipid;
preferably, the molar ratio of the polymer-conjugated lipid to the carrier is from 0.5% to 5%;
preferably, the polymer-conjugated lipid is selected from one or more of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, and PEG-modified dialkylglycerol; or
preferably, the polymer-conjugated lipid is selected from one or more of distearoyl phosphatidylethanolamine polyethylene glycol 2000 (DSPE-PEG2000), dimyristoylglycero-3-methoxy polyethylene glycol 2000 (DMG-PEG2000) and methoxypolyethylene glycol ditetradecylacetamide (ALC-0159).

### Claim 8 (depends on 3)

The composition according to claim 3, wherein the carrier comprises a cationic lipid, a neutral lipid, a structured lipid and a polymer-conjugated lipid, and the molar ratio of the cationic lipid, the neutral lipid, the structured lipid and the polymer-conjugated lipid is (25-65):(5-25):(25-45):(0.5-5);
preferably, the molar ratio of the cationic lipid, the neutral lipid, the structured lipid, and the polymer-conjugated lipid is 50:10:38.5:1.5.

### Claim 9 (depends on 3)

The composition according to claim 3, wherein the composition is a nanoparticle formulation which has an average particle size of 10 nm to 210 nm and a polydispersity coefficient less than or equal to 50%;
preferably, the composition is a nanoparticle formulation which has an average particle size of 100 nm to 205 nm and a polydispersity coefficient less than or equal to 30%.

### Claim 10 (depends on 3)

The composition according to claim 3, wherein the cationic lipid further comprises one or more other ionizable lipid compound(s).

### Claim 11 (depends on 3)

The composition according to claim 3, further comprising a therapeutic or prophylactic agent.

### Claim 12 (depends on 11)

The composition according to claim 11, wherein the mass ratio of the carrier to the therapeutic agent or prophylactic agent is from 10:1 to 30:1;
preferably, the mass ratio of the carrier to the therapeutic agent or prophylactic agent is from 15:1 to 25:1;
more preferably, the mass ratio of the carrier to the therapeutic agent or prophylactic agent is 16:1.

### Claim 13 (depends on 11)

The composition according to claim 11, wherein the therapeutic or prophylactic agent comprises one or more of a nucleic acid molecule, a small molecule compound, a polypeptide or a protein.

### Claim 14 (depends on 11)

The composition according to claim 11, wherein the therapeutic or prophylactic agent is a vaccine or compound capable of eliciting an immune response.

### Claim 15 (depends on 11)

The composition according to claim 11, wherein the therapeutic or prophylactic agent is a nucleic acid;
preferably, the therapeutic or prophylactic agent is ribonucleic acid (RNA), more preferably, the RNA is selected from the group consisting of small interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), Dicer-substrate RNA (dsRNA), small hairpin RNA (shRNA), messenger RNA (mRNA), and mixtures thereof; or
preferably, the therapeutic or prophylactic agent is deoxyribonucleic acid (DNA).

### Claim 16 (depends on 11)

The composition according to claim 11, wherein the composition further comprises one or more of pharmaceutically acceptable excipients or diluents.

### Claim 17 (depends on 1)

A method of treating a disease or condition in a mammal, comprising administering the compound of formula (I) or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof according to claim 1 to a subject in need thereof;
preferably, the disease or condition is characterized by dysfunctional or abnormal protein or polypeptide activity;
preferably, the disease or condition is selected from the group consisting of infectious diseases, cancer and proliferative diseases, genetic diseases, autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular and renovascular diseases, and metabolic diseases; or
more preferably, the infectious disease is selected from: diseases caused by coronavirus, influenza virus or HIV virus, infantile pneumonia, Rift Valley fever, yellow fever, rabies, and various herpes.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the mammal is a human.

### Claim 19 (depends on 17)

The method according to claim 17, wherein the composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally or by inhalation; preferably, the composition is administered subcutaneously.

### Claim 20 (depends on 17)

The method according to claim 17, wherein the therapeutic or prophylactic agent is administered to the mammal at a dose of about 0.001 mg/kg to about 10 mg/kg.
